Stratos Wealth Partners LTD. Decreases Stake in Zoetis Inc. (NYSE:ZTS)

Stratos Wealth Partners LTD. decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,884 shares of the company's stock after selling 1,678 shares during the period. Stratos Wealth Partners LTD.'s holdings in Zoetis were worth $10,848,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ZTS. Brighton Jones LLC lifted its position in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after buying an additional 2,978 shares in the last quarter. Bank Pictet & Cie Europe AG lifted its position in shares of Zoetis by 5.4% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 419,530 shares of the company's stock valued at $68,354,000 after buying an additional 21,470 shares in the last quarter. Proficio Capital Partners LLC lifted its position in shares of Zoetis by 61.0% during the 4th quarter. Proficio Capital Partners LLC now owns 3,053 shares of the company's stock valued at $497,000 after buying an additional 1,157 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Zoetis by 5.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 217,094 shares of the company's stock valued at $35,371,000 after buying an additional 12,174 shares in the last quarter. Finally, Isthmus Partners LLC lifted its position in shares of Zoetis by 0.3% during the 4th quarter. Isthmus Partners LLC now owns 68,821 shares of the company's stock valued at $11,213,000 after buying an additional 173 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Piper Sandler raised their price objective on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, UBS Group decreased their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $212.13.

Zoetis Trading Up 0.4%

ZTS traded up $0.67 during trading hours on Tuesday, reaching $157.72. The company's stock had a trading volume of 2,885,127 shares, compared to its average volume of 2,575,010. The stock has a market cap of $70.22 billion, a PE ratio of 28.32, a P/E/G ratio of 2.64 and a beta of 0.91. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. The business's 50-day moving average is $161.23 and its 200-day moving average is $162.02.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The company's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.38 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.